MEM — Memphasys Share Price
0.000.00%
Last trade - 00:00- AU$8.86m
- AU$12.63m
- AU$0.06m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.46 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 319.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -73.24% | ||
| Return on Equity | -80.47% | ||
| Operating Margin | -16883% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | 0.03 | 0.02 | 0.06 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Directors
- Alison Coutts CHM
- Tom Rowe GCN
- John Aitken OTH
- John Andrews OTH
- Thee Goh OTH
- Matthew Loggie OTH
- Andrew Metcalfe SEC
- Andrew Goodall NED
- Shane Hartwig NED
- Paul Wright NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 11th, 2006
- Public Since
- May 14th, 2007
- No. of Shareholders
- 2,132
- No. of Employees
- 24
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,771,014,766
- Address
- 30 Richmond Rd, HOMEBUSH WEST, 2140
- Web
- https://www.memphasys.com/
- Phone
- +61 284157300
- Auditors
- Pitcher Partners
Upcoming Events for MEM
Similar to MEM
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Memphasys share price?
As of Today at 22:00 UTC, shares in Memphasys are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Memphasys share price performed this year?
Shares in Memphasys last closed at AU$0.01 and the price had moved by -37.5% over the past 365 days. In terms of relative price strength the Memphasys share price has underperformed the ASX All Ordinaries Index by -39.76% over the past year.
What are the analyst and broker recommendations for Memphasys?
There is no consensus recommendation for this security.
Find out moreWhat is the Memphasys dividend yield?
Memphasys does not currently pay a dividend.
Does Memphasys pay a dividend?
Memphasys does not currently pay a dividend.
When does Memphasys next pay dividends?
Memphasys does not currently pay a dividend.
How do I buy Memphasys shares?
To buy shares in Memphasys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Memphasys?
As of the previous close price of AU$0.01, shares in Memphasys had a market capitalisation of AU$8.86m.
Where are Memphasys shares listed?
Here are the trading details for Memphasys:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MEM
What kind of share is Memphasys?
Based on an overall assessment of its quality, value and momentum Memphasys is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Memphasys share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Memphasys share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Memphasys. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -26.52%.
As of the last closing price of AU$0.01, shares in Memphasys were trading -33.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Memphasys PE Ratio?
The Memphasys PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Memphasys?
Memphasys' management team is headed by:
- Alison Coutts - CHM
- Tom Rowe - GCN
- John Aitken - OTH
- John Andrews - OTH
- Thee Goh - OTH
- Matthew Loggie - OTH
- Andrew Metcalfe - SEC
- Andrew Goodall - NED
- Shane Hartwig - NED
- Paul Wright - NID